Taking advantage of the French annual dermatologic conference "Journées Dermatologiques de Paris" that took place in December 2015, this article highlights the latest clinical advances, which occurred in autoimmune, inflammatory and systemic diseases during the past year. Evaluations of new classifications, new prognostic factors, and significant results of clinical trials in such diseases are underlined. A special attention is given to the classifications of systemic lupus erythematosus and systemic sclerosis as well as the use of rituximab in idiopathic thrombocytopenic purpura or in the maintenance treatment of patients with anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Keywords: Anti-neutrophil cytoplasmic antibodies-associated vasculitis; Idiopathic thrombocytopenic purpura; Internal medicine; Lupus érythémateux systémique; Médecine interne; Purpura thrombopénique idiopathique; Sclérodermie systémique; Systemic lupus erythematosus; Systemic sclerosis; Vascularites associées aux anticorps anticytoplasme des polynucléaires neutrophiles.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.